A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

NCT05890287 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

HR Positive HER2 Negative Advanced Breast Cancer

Interventions

DRUG: Chidamide

Sponsor

Tianjin Medical University Cancer Institute and Hospital